OncoCyte (NASDAQ:OCX) Earns Sell Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of OncoCyte (NASDAQ:OCX) in a research note released on Friday. The firm issued a sell rating on the stock.

Separately, Needham & Company LLC reiterated a buy rating and set a $4.25 target price on shares of OncoCyte in a report on Friday, August 9th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of Hold and an average target price of $4.06.

OncoCyte Stock Performance

OncoCyte stock opened at $2.88 on Friday. The business has a 50-day simple moving average of $3.11 and a 200 day simple moving average of $2.93. OncoCyte has a 52 week low of $2.08 and a 52 week high of $4.34.

OncoCyte (NASDAQ:OCX) last released its earnings results on Thursday, August 8th. The company reported ($0.36) earnings per share for the quarter. OncoCyte had a negative net margin of 3,558.46% and a negative return on equity of 149.88%. The company had revenue of $0.10 million during the quarter.

About OncoCyte

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.